Company Overview and News

 
Medibio Announces Executive Leadership Changes

10h globenewswire
SYDNEY, Australia and MINNEAPOLIS, Minn., Sept. 21, 2018 (GLOBE NEWSWIRE) -- The Board of Medibio Limited (MEB or the Company)(ASX: MEB)(OTCQB: MDBIF), today announced several changes to the Company’s executive leadership team.
MEB

 
Departure of Managing Director & Chief Executive Officer

2018-08-29 globenewswire
SYDNEY, Australia and MINNEAPOLIS, Aug. 29, 2018 (GLOBE NEWSWIRE) -- The Board of Medibio Limited (MEB or the Company)(ASX: MEB)(OTCQB: MDBIF), today announced that Mr. Jack Cosentino will cease as Managing Director and Chief Executive Officer of the Company. His departure is effective from August 28, 2018. Mr. Cosentino was appointed Managing Director and Chief Executive Officer on February 16, 2017.
MEB

 
Medibio Submits FDA De Novo Application

2018-07-16 globenewswire
SYDNEY, Australia and MINNEAPOLIS, July 16, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company)(ASX:MEB)(OTCQB:MDBIF), a mental health technology company, today announced the U.S. Food and Drug Administration (FDA) De Novo submission for its Clinical Decision Support System (System) and the first of many modules that addresses the aid to the diagnosis of mental health disorders. The formal submission to the FDA was completed on Friday, July 13, following the successful 230-person clinical study at eight clinical sites and an in-person meeting with key members of the FDA and Medibio leadership team.
MEB

 
Peer-reviewed Neurology Publication on Medibio Science

2018-06-26 globenewswire
SYDNEY, Australia and MINNEAPOLIS, June 26, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company) (ASX:MEB) (OTCQB:MDBIF), a mental health technology company, announces that a clinical article by Defillo et al. titled “Physiological Differences between Mood Disorder Phenotypes Based on Heart Rate Variability” has been accepted for publication in EC Neurology, an internationally peer-reviewed journal.
MEB

 
Medibio Receives TGA Approval

2018-06-19 globenewswire
SYDNEY, Australia and MINNEAPOLIS, June 19, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company)(ASX:MEB)(OTCQB:MDBIF), a mental health technology company, announced today it has received confirmation that the Company’s Depression Diagnostic Aide (DDA) and Mental Health Monitoring Platform (MHM) have been included on the register of Australian Therapeutic Goods Administration (ATGA). Medibio’s DDA and MHM technology underpin the Company’s Mental Index application and Logics platform.
MEB

 
Medibio Broadens Opportunities with Compatibility to Fitbit Wearable Devices for Mental Health Measurement

2018-06-13 globenewswire
SYDNEY, Australia and MINNEAPOLIS, June 13, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (ASX:MEB) (OTCQB:MDBIF), the world leader in objective measurement technology for mental health, has recently enhanced the compatibility of its mobile app product to accept data from Fitbit devices equipped with heart rate monitors.
MEB

16
Medibio Announces Next Tranche of Corporate Health Contracts

2018-05-10 globenewswire
SYDNEY, Australia and MINNEAPOLIS, May 09, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company)(ASX:MEB) (OTCQB:MDBIF), a mental health technology company, is pleased to confirm the next tranche of corporate clients to join the Company’s Corporate Mental Health Check-in.
RTPPF RIO RIO MEB RIO RTNTF

 
Medibio Corporate Health contract signed with Australia’s 3rd largest private healthcare provider

2018-05-09 globenewswire
SYDNEY, Australia and MINNEAPOLIS, May 08, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company) (ASX:MEB) (OTCQB:MDBIF), a mental health technology company, today announced the execution of a commercial contract with St. John of God Health Care (SJGHC) to deploy Medibio’s new product for its newly established Corporate Health division.
MEB

 
Medibio Receives CE Certification

2018-05-03 globenewswire
SYDNEY, Australia and MINNEAPOLIS, May 02, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company) (ASX:MEB) (OTCQB:MDBIF), a mental health technology company, is pleased to confirm it has received CE (Conformité Européenne) Marking certification for its first release technology product and platform.
MEB

 
Medibio Launches Global Corporate Mental Health Product

2018-05-01 globenewswire
SYDNEY, Australia and MINNEAPOLIS, April 30, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company)(ASX:MEB)(OTCQB:MDBIF), a mental health technology company confirms the launch and release of the Company’s Corporate Mental Health for business product and platform (the Platform).
MEB

 
Medibio Announces Scientific Advisory Board

2018-04-26 globenewswire
SYDNEY, Australia and MINNEAPOLIS, April 25, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company) (ASX:MEB) (OTCQB:MDBIF), a mental health technology company confirms establishment of its Scientific Advisory Board (SAB).
MEB MLPH

 
Medibio shares rise following recent acquisition of Vital Conversations

2018-04-09 proactiveinvestors.com.au
Medibio Ltd (ASX:MEB), a mental health technology company, is one of the top performing companies on the ASX today with its shares trading up 30% to 19.5 cents after midday.
MEB

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to ASX:MEB / MEDIBIO LIMITED on message board site Silicon Investor.

$2 or higher gas - Can ethanol make a comeback? $2 or higher gas - Can ethanol make a comeback? $2 or higher gas - Can ethanol make a comeback? Donu0027t abuse it, reuse it! ARCI makes the big comeback. Donu0027t abuse it, reuse it! ARCI makes the big comeback. Donu0027t abuse it, reuse it! ARCI makes the big comeback.
BOILER ROOM OPERATOR BRYANT CRAGUN MAKES COMEBACK. BOILER ROOM OPERATOR BRYANT CRAGUN MAKES COMEBACK. BOILER ROOM OPERATOR BRYANT CRAGUN MAKES COMEBACK. Beaten-down Stocks Ready For A Comeback Beaten-down Stocks Ready For A Comeback Beaten-down Stocks Ready For A Comeback
SWMCF- Making a comeback this week. SWMCF- Making a comeback this week. SWMCF- Making a comeback this week. Macromedia...making a comeback? Macromedia...making a comeback? Macromedia...making a comeback?
WTZRA -Weitzer Homebuilders Inc/Century Ptnrs. Low float!! WTZRA -Weitzer Homebuilders Inc/Century Ptnrs. Low float!! WTZRA -Weitzer Homebuilders Inc/Century Ptnrs. Low float!! Applied Theory ( ATHY ) - looking for a big comeback Applied Theory ( ATHY ) - looking for a big comeback Applied Theory ( ATHY ) - looking for a big comeback
TMBT - Timebeat.com Enterprises Inc. (OTC BB: TMBT) TMBT - Timebeat.com Enterprises Inc. (OTC BB: TMBT) TMBT - Timebeat.com Enterprises Inc. (OTC BB: TMBT) HOMEBASE (HBI) HOMEBASE (HBI) HOMEBASE (HBI)